US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for ...

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...

People with breathing problems during sleep may have a larger hippocampus, the area of the brain responsible for memory and ...

This pattern often signals obstructive sleep apnea (OSA), a condition where breathing ... Over time, this repeated stress can ...

An estimated 39 million American adults suffer from obstructive sleep apnea, a condition in which the upper airway is blocked ...

Sleep disordered breathing is a range of conditions that cause abnormal breathing during sleep including snoring and ...

Sleep apnea is a condition in which breathing stops intermittently while a person sleeps. Read more at straitstimes.com.

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

Even before the FDA approval, some doctors have been prescribing weight-loss drugs to people with sleep apnea.

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.